Health Guide
Compound Library
Plain-English summaries: what it is, what it was studied for, safety and regulatory status, plus mixing and dosing charts.
An investigational once-weekly medicine from Eli Lilly that activates three hormone receptors: GIP, GLP-1 and glucagon.
A 16-amino-acid peptide encoded by mitochondrial DNA, studied for energy metabolism, insulin sensitivity and exercise.
Two compounds that act on growth-hormone signaling in different ways.
An FDA-approved prescription peptide that activates both GIP and GLP-1 receptors.
The active ingredient in several FDA-approved GLP-1 medicines.
An experimental 15-amino-acid peptide studied for tissue repair in lab and animal models.
Usually refers to a short, modified fragment of thymosin beta-4, not the full-length peptide used in most of the studies cited to support it.
A popular pairing in injury-recovery discussions. Most of the supporting work involves each compound separately in cells or animals; there is no controlled human trial of the blend.
One of the most discussed growth hormone pairings, sold both premixed (usually no-DAC CJC-1295) and as separate vials (often DAC CJC-1295).
A copper-binding peptide found in human plasma and studied in skin biology, cosmetics and wound repair.
A five-amino-acid peptide that triggers growth hormone release.
An FDA-approved prescription peptide that reduces excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy.
NAD+ is not a peptide; it is a coenzyme every cell uses for energy reactions.
An investigational combination of an amylin analogue and a GLP-1 receptor agonist.
A three-ingredient research blend promoted for skin quality and recovery.
A four-ingredient research blend marketed for recovery, skin and inflammation.
A 16-amino-acid fragment of human growth hormone studied for fat metabolism.
Bremelanotide is the active ingredient in Vyleesi, FDA approved in 2019 for a specific form of low sexual desire in premenopausal women.
A synthetic peptide that can darken skin. Regulators warn about serious side effects and unknown product contents, and a tan from it does not protect against sun damage.
A short-acting growth-hormone-releasing hormone (GHRH) analogue.
A long-acting growth-hormone-releasing hormone analogue that raises growth hormone and IGF-1 for days in humans.
A peptide that prompts the pituitary to release growth hormone.
An experimental four-amino-acid peptide studied for telomeres, aging and circadian rhythms.
A seven-amino-acid peptide studied mainly for anxiety in small Russian trials.
A seven-amino-acid peptide derived from ACTH and used clinically in Russia.
A natural reproductive hormone signal that sits upstream of GnRH, LH and FSH.
A four-amino-acid peptide that targets mitochondria. In September 2025 the FDA granted accelerated approval to Forzinity (elamipretide) for muscle strength in Barth syndrome, a rare genetic disorder.
An investigational long-acting amylin analogue for weight management.
A modified IGF-1 used in lab research. It is biologically active, but muscle-building, recovery and anti-aging claims are not established, and it is not the approved IGF-1 medicine.
An experimental small molecule, not a peptide, that blocks the enzyme NNMT.
A three-amino-acid molecule your cells make to manage oxidative stress.
"191AA" just describes the 191-amino-acid human growth hormone molecule; somatropin is the recombinant prescription version.
A three-amino-acid peptide from the end of alpha-MSH, studied for anti-inflammatory activity in experimental gut inflammation.
An experimental nine-amino-acid peptide whose name is more confident than its evidence.
An immune-regulating peptide studied in people with specific illnesses.
A natural 37-amino-acid antimicrobial peptide involved in immune defense.
A dual GLP-1/glucagon receptor agonist approved in China in 2025 for weight management and type 2 diabetes.
An investigational once-weekly peptide that activates both GLP-1 and glucagon receptors, studied for obesity and fatty liver disease (MASH).
A pregnancy hormone with specific prescription uses in fertility care and some hormone conditions.
A synthetic version of gonadotropin-releasing hormone (GnRH), the signal that tells the pituitary to release LH and FSH.
A peptide hormone with established hospital uses in childbirth and a much less settled role in research on social behavior, appetite and sexual function.
An experimental small molecule, not a peptide, that activates estrogen-related receptors (ERRs) involved in energy use.
A synthetic peptide that stimulates growth hormone release through the ghrelin receptor.
A synthetic peptide that triggers growth hormone release and increases appetite.
A research blend that combines TB-500, BPC-157 and KPV. Each ingredient has its own early research, but the combination itself has not been tested in a controlled human trial.
A three-ingredient combination often discussed for fat loss and body composition.
A synthetic alpha-MSH analogue. As the Scenesse implant (afamelanotide), it is FDA approved for a rare light-sensitivity disorder, not for cosmetic tanning.
An eight-amino-acid cosmetic ingredient used in anti-wrinkle products.
A three-amino-acid synthetic peptide studied as a "bioregulator." Laboratory work on stressed nerve cells is interesting, but it has not been shown to treat memory, sleep, or aging problems in people.
An investigational peptide studied for small-fiber nerve damage (neuropathy).
An experimental metabolic compound, not a peptide, widely used in labs to activate AMPK, the cell's energy sensor.
An amino-acid derivative the body uses to move fatty acids into mitochondria for energy.
A small peptide encoded by mitochondrial DNA and studied for cell survival, metabolism and aging.
An experimental "senolytic" peptide designed to trigger the removal of certain aging (senescent) cells.
A name tied to research on how the IGF-1 system responds to muscle loading.
A pegylated version of mechano growth factor peptide, discussed in muscle-repair research.
An injectable mixture of peptides and amino acids derived from pig brain, studied in stroke, dementia and brain injury with mixed results.
An experimental compound designed to destroy the blood supply of white fat tissue.
An investigational once-weekly amylin receptor agonist being developed by Lilly for obesity.
An experimental seven-amino-acid peptide that blocks the TREK-1 potassium channel, studied as a new approach to depression research.
A research-blend name for a four-ingredient cognitive formulation.
A prescription fertility medicine that supplies both FSH and LH activity.
A research blend pairing a GHRH analogue with a ghrelin-receptor secretagogue.
A copper-binding tripeptide related to GHK-Cu, studied mainly for hair follicles.
A pairing of two melanocortin-receptor peptides sold as separate vials.
An FDA-approved prescription medicine that builds bone in people with osteoporosis at high fracture risk.
An FDA-approved prescription bone-building medicine for osteoporosis in adults at high fracture risk.
A three-amino-acid bioregulator peptide studied for effects on blood-vessel lining cells.
A four-amino-acid bioregulator peptide studied mainly in lab models of chromatin, protein synthesis and digestive enzymes.
A four-amino-acid bioregulator peptide studied in heart-tissue cultures and animals.
A three-amino-acid bioregulator peptide studied in cartilage cells and cellular aging.
A four-amino-acid bioregulator peptide studied for nerve tissue and gene expression.
A four-amino-acid synthetic peptide. Despite its name, the best-identified hormone studies involve thyroid function in birds, not testosterone in men.
A four-amino-acid bioregulator peptide studied in prostate tissue and cellular-aging experiments.
A two-amino-acid synthetic peptide studied in immune-cell and aging research.
A four-amino-acid research peptide studied in airway cells and experimental lung-injury models.
A three-amino-acid bioregulator peptide studied for effects on inflammatory signaling.
A short tripeptide marketed as a liver or digestive "bioregulator." The clearest published experiments involve kidney cells and older rats, not liver disease in people.
A research-product name marketed as a Semax-related nootropic.
An experimental peptide that damages cancer cell membranes in lab and animal studies.